]-vasopressin (AVP) and oxytocin (OT) are neurohypophysial hormones which exert various actions, including the control of blood glucose, in some peripheral tissues. To investigate the type of receptors involved in AVP-and OT-induced glucagon secretion, we investigated the effect of these peptides on glucagon secretion in islets of wild-type (V1bRC/C) and vasopressin V1b receptor knockout (V1bRK/K) mice. AVP-induced glucagon secretion was significantly inhibited by the selective V1b receptor antagonist, SSR149415 (30%), and OT-induced glucagon secretion by the specific OT receptor antagonist, dðCH 2 Þ 5 ½TyrðMeÞ 2 ; Thr 4 ; Tyr-NH 9 2 OVT (CL-14-26) (45%), in islets of V1bRC/Cmice. AVP-and OT-induced glucagon secretions were not by the antagonist of each, but co-incubation with both 10 K6 M SSR149415 and 10 K6 M CL-14-26 further inhibited AVP-and OT-induced glucagon secretions in islets of V1bRC/C mice (57 and 69% of the stimulation values respectively). In addition, both AVP and OT stimulated glucagon secretion with the same efficacy in V1bRK/K mice as in V1bRC/C mice. AVP-and OT-induced glucagon secretion in V1bRK/K mice was significantly inhibited by CL-14-26. These results demonstrate that V1b receptors can mediate OT-induced glucagon secretion and OTreceptors can mediate AVP-induced glucagon secretion in islets from V1bRC/C mice in the presence of a heterologous antagonist, while AVP and OT can stimulate glucagon secretion through the OT receptors in V1bRK/K mice, suggesting that the other receptor can compensate when one receptor is absent.
Introduction
Arginine-vasopressin (AVP) and oxytocin (OT) are neurohypophysial hormones synthesized in the paraventricular nucleus and supraoptic nucleus of the hypothalamus. AVP acts in many organs and plays a variety of physiological roles, such as vasoconstriction (Schrier et al. 1993) , glycogenolysis in the liver (Michell et al. 1979 , Eugenin et al. 1998 , adrenocorticotropic hormone (ACTH) release from the anterior pituitary (Gillies et al. 1982 , Rivier et al. 1984 , Hernando et al. 2001 , and water reabsorption in the kidney (Nielsen et al. 1995 , Ecelbarger et al. 2000 . OT also plays crucial roles in uterine contraction (Fuchs et al. 1982 , Goodwin et al. 1994 ) and milk ejection during lactation (Moos et al. 1989 , Young et al. 1996 . In addition to these physiological roles, AVP and OT are known to regulate the circulating blood glucose level by stimulating insulin and glucagon release (Dunning et al. 1984 , Gao et al. 1990 , 1991 , Stock et al. 1990 , Li et al. 1992 , Gao & Henquin 1993 , Abu-Basha et al. 2002 .
AVP-and OT-induced pancreatic hormone secretion, such as insulin and glucagon, is evoked by the activation of AVP and OT receptors expressed in pancreatic islet cells.
These AVP and OT receptors are seven transmembrane G-protein-coupled receptors and belong to the same family. This receptor family consists of the V1a, V1b, and V2 receptors and the OT receptor. Several studies have reported that the V1b and OT receptors are involved in insulin and glucagon secretion from a pancreatic cell line (Richardson et al. 1995 , Yibchok-anun & Hsu 1998 or isolated islets . While insulin secretion by AVP (Richardson et al. 1995 and OT (Lee et al. 1995) has been shown to be induced via the V1b receptor, previous studies with subtype-nonselective vasopressin receptor antagonists suggested that both the V1b and the OT receptors were involved in glucagon secretion by stimulation with AVP and OT (Yibchok-anun & Hsu 1998 , Yibchok-anun et al. 1999 . Although both V1b and OT receptors are involved in the glucagon secretion, no one has analyzed this secretion when specific receptor is absent.
To elucidate the roles of the V1b receptor in glucagon secretion, we examined the mechanism of AVP-and OT-induced glucagon secretion using receptor-selective antagonists and V1b receptor knockout (V1bRK/K) mice , in which tissue expression of the V1b receptor mRNA was undetectable . First, we examined whether SSR149415, a recently developed V1b receptor-specific antagonist (Serradeil-Le Gal et al. 2002 , Folny et al. 2003 , inhibited AVP-and OT-induced glucagon secretion from primary cultured mouse islet cells. We next investigated the involvement of the OT receptor in AVP-and OT-induced glucagon secretion using dðCH 2 Þ 5 ½TyrðMeÞ 2 ; Thr 4 ; Tyr-NH 9 2 OVT (CL-14-26), an OTreceptor-selective antagonist. Furthermore, we investigated glucagon secretion in V1bRK/K mice with the antagonists. We show here that both the V1b and the OT receptors fundamentally mediate AVP-and OT-induced glucagon secretion respectively, and that signaling pathways through the OT receptor can mediate and compensate AVP-induced glucagon secretion when the V1b receptor is completely abolished.
Materials and Methods

Materials
Fetal bovine serum (FBS) was from Thermo Trace (Melbourne, Australia). Hanks' solution was from Nissui (Tokyo, Japan). AVP and OT were from the Peptide Institute (Osaka, Japan OVT (CL-14-26), which specifically antagonized the OT receptor (Elands et al. 1988 , Kawamata et al. 2003 , was a generous gift from Dr Maurice Manning (Medical College of Ohio). The RPMI 1640 medium, BSA, and diethylstilbestrol dipropionate (DES) were purchased from Sigma-Aldrich (Tokyo, Japan). Collagenase S-1 was purchased from Nitta (Osaka, Japan). Glucagon ELISA kits and all other chemicals were purchased from WAKO (Tokyo, Japan).
Animals
Male mice deficient in the V1b vasopressin receptor were generated by gene targeting as described previously . Briefly, by homologous recombination, we disrupted exon 1, which contains the translation initiation codon. The generated mutant mice were of a mixed genetic background of 129Sv and C57BL/6. For this study, wild-type (V1bRC/C) mice were used as controls and maintained on the 129Sv and C57BL/6 genetic background. All animals used in this study were 9-10 weeks old. Mice were housed in micro-isolator cages in a pathogen-free barrier facility (12 h light:12 h darkness cycle) with access to regular chow and water available ad libitum. All experiments followed the institutional guidelines.
Isolation of pancreatic islets and glucagon measurement
Mouse pancreatic islets were isolated from male mice by collagenase digestion followed by Ficoll gradient separation as described previously (Shibata et al. 1976 . Briefly, the mouse pancreas was injected with an aliquot of 3 ml Hanks' medium containing 2 mg/ml collagenase S-1 through the choledoch duct by clamping one side of the duct to block the flow into the intestinal tract. Pancreata were collected from four to five mice, and incubated at 37 8C for 20 min. The reaction was stopped by the addition of ice-cold Hanks' medium. The digested pancreata were washed with the same medium, filtrated through a Spectra-mesh (408 mm; Spectrum Laboratories, Inc., Ft. Lauderdale, FL, USA), and washed with the same medium. The samples were resuspended in 4 ml Ficoll (specific gravity, 1 . 22) and then overlaid twice with 2 ml Ficoll with specific gravities of 1 . 09 and 1 . 05. After centrifugation at 2000 g for 10 min, the islets were collected from the interface. The isolated islets were washed with an RPMI 1640 medium containing 10% FBS, 11 mM glucose, 50 U/ml penicillin, and 50 mg/ml streptomycin and preincubated for 2-3 h in the same medium at 37 8C in 5% CO 2 . Fifteen islets were used for one assay, and experiments including three or four assays in one dose were repeated four to five times. After sampling of the baseline, AVP or OT stimulation was performed at 37 8C for 10 min. Arginine (20 mM) was used as a positive control. Each antagonist was added 5 min before the stimulation with AVP or OT. After stimulation, the supernatant was taken up and the glucagon concentration was measured using the glucagon ELISA kit.
Ligand binding assay
Uterine tissues were isolated from female mice treated with DES (0 . 3 mg/kg body weight) i.p., 20 h before isolation.
Uterine cells stably expressing mouse V1b receptor were prepared as described previously . Saturation binding studies were performed to incubate 20 mg cell membrane and 50 mg uterine membrane preparations with various concentrations of [ 3 H]AVP and [
The filters were rinsed five times, and the radioactivity was measured using a TopCount Microplate Scintillation Counter (Perkin-Elmer Life Science and Analytical Sciences). Nonspecific binding was determined using 1 mM unlabeled AVP and OT. Specific binding was calculated as the difference between total and nonspecific counts. The inhibitory K d values (K i ) were calculated using the following formula (Cheng & Prusoff 1973) : (Munson & Rodbard 1980) .
Statistical analysis
Data are expressed as meansGstandard error (S.E.M.). Statistical analysis was performed using the unpaired Student's t-test and the one-or two-way ANOVA followed by a post hoc comparison with Fisher's probable least-squares differences (PLSD) test using Statview version 5.0 software (Concepts, Inc., Berkeley, CA, USA). Differences between groups were considered statistically significant at the level of P!0 . 05.
Results
AVP-and OT-induced glucagon secretion from the islets of V1bRC/C mice AVP increased glucagon secretion from the islets of V1bRC/C mice in a dose-dependent manner (Fig. 1A) . AVP-induced glucagon secretion in V1bRC/C mice was five times the value at the baseline after stimulation of 10 K8 M, which was a sufficient concentration to release glucagon under the conditions of this experiment (glucagon secretion at 10 K8 vs 10 K7 M of AVP, PZ0 . 39). The basal glucagon concentration was 355 . 1G59 . 4 pg/ml in AVP-stimulation experiments. OT-induced glucagon secretion was six times that at the baseline at 10 K7 M, which was a sufficient concentration to release glucagon in V1bRC/C mice (the glucagon secretion at 10 K8 vs 10 K7 M AVP, P!0 . 01; Fig. 1B ). Basal Table 1 The receptor affinity of AVP, OT, and compounds for the V1b and the OT receptors (OTR) Y FUJIWARA and others . AVP-and oxytocin-induced glucagon secretion glucagon concentration was 386 . 7G47 . 4 pg/ml in OT-stimulation experiments. Glucagon secretion by arginine stimulation in this experiment was approximately four times that at the baseline and lower than that by AVP or OT stimulation (Fig. 1) .
Analysis of AVP-and OT-induced glucagon secretion with receptor-selective antagonists in V1bRC/C mice Antagonists were used to identify the receptors involved in glucagon secretion from the islets of V1bRC/C mice. We selected and used SSR149415 as a V1b receptor-specific antagonist that was used in a previous experiment . In this study, we examined the specificity of CL-14-26 for a mouse OT receptor using a radioligand binding assay using the uterine plasma membrane of female mice treated with DES. respectively. SSR149415 significantly inhibited AVP-induced glucagon secretion from the islets of V1bRC/C mice at 10 K6 M ( Fig. 2A) . Around 30% inhibition was observed at 10 K6 M SSR149415, whereas, from 10 K9 to 10 K6 M, CL-14-26 could not significantly inhibit AVP-induced glucagon secretion from the islets of V1bRC/C mice (Fig. 2B) . Furthermore, the OT-selective antagonist, CL-14-26, significantly inhibited OT-induced glucagon secretion from the islets of V1bRC/C mice at 10 K6 M (Fig. 2C ). Around 45% inhibition was observed at 10 K6 M CL-14-26, whereas 10 K6 M SSR149415 tended to suppress OT-induced glucagon secretion, but not significantly (Fig. 2C) . These results indicated that AVP and OT stimulated glucagon secretion through the V1b and OT receptors respectively, in V1bRC/C mice.
Since AVP-and OT-induced glucagon secretion was not completely inhibited by SSR149415 or CL-14-26 even at the highest concentration (10 K6 M), we studied glucagon secretion further with a combination of the V1b and OT receptor antagonists. Simultaneous administration of SSR149415 and CL-14-26 synergistically inhibited AVPand OT-induced glucagon secretion at a concentration of 10 K6 M ( Fig. 2A and C) . The percentage inhibition of SSR149415 in AVP-induced glucagon secretion was increased from 30 to 57% in combination with CL-14-26. Similarly, the percentage inhibition of SSR149415 in OT-induced glucagon secretion was increased from 45 to 69% in combination with CL-14-26. There were no significant differences between the basal levels and either AVP or OT stimulation in combination with both SSR149415 and CL-14-26 (one-way ANOVA; PZ0 . 52 in AVP stimulation, PZ0 . 33 in OT stimulation). These results suggested that AVP could stimulate glucagon secretion via the OT receptors, when the V1b receptor was blocked by SSR149415; and that OT could also stimulate it via the V1b receptors, when the OT receptor was blocked by CL-14-26.
AVP-and OT-induced glucagon secretion from the islets of V1bRK/K mice We examined AVP-and OT-induced glucagon secretion from the islets of V1bRK/K mice (Fig. 3) . Not only OT but also AVP was able to stimulate glucagon secretion in V1bRK/K mice in a dose-dependent manner, as observed in V1bRC/C mice ( Fig. 3A and B) . In V1bRK/K mice, AVP-and OT-induced glucagon secretion was about six times that at the baseline at 10 K7 M, which was a sufficient concentration to release glucagon under the conditions of this experiment (glucagon secretion at 10 K8 vs 10 K7 M AVP, P!0 . 05; glucagon secretion at 10 K8 vs 10 K7 M OT, P!0 . 01). The basal glucagon concentrations were 340 . 8G 52 . 7 and 339 . 5G20 . 8 pg/ml in AVP-and OT-stimulation experiments respectively. There were no significant differences in AVP-and OT-induced glucagon secretion between V1bRC/C and V1bRK/K mice (V1bRC/C mice versus V1bRK/K mice; PZ0 . 85 for AVP-stimulation experiments, and PZ0 . 81 for OT-stimulation experiments by two-way ANOVA). Glucagon secretion by arginine stimulation in this experiment was approximately four times that at the baseline and lower than that by AVP or OT stimulation, similar to the observation in V1bRC/C mice (Fig. 3) . These findings suggested that AVP could stimulate glucagon secretion via a receptor(s) other than the V1b receptor in V1bRK/K mice as potently as OT could. Next, we examined glucagon secretion with antagonists to elucidate the receptors involved in AVP-induced glucagon secretion in V1bRK/K mice. While 10 K6 M SSR149415 could not suppress AVP-or OT-induced glucagon secretion, CL-14-26 could significantly inhibit AVP-and OT-induced glucagon secretion (Fig. 4) . In particular, CL-14-26 could almost completely inhibit AVP-induced glucagon secretion at a concentration of 10 K6 M in V1bRK/K mice, whereas it did not significantly antagonize AVP-induced glucagon secretion in V1bRC/C mice. There were no significant differences between the basal level and either AVP or OT stimulation in combination with CL-14-26 in V1bRK/K mice (one-way ANOVA; PZ0 . 50 in AVP stimulation, PZ0 . 12 in OT stimulation). This suggested that AVP and OT stimulate glucagon secretion through the OT receptor in V1bRK/K mice, in which a signaling pathway of the OT receptors could achieve optimal efficacy by stimulation of even OT and AVP.
We conducted further experiments to reveal the response to co-stimulation of AVP and OT in V1bRC/C and V1bRK/K mice. In V1bRC/C mice, glucagon secretion by co-stimulation was higher than single stimulation of AVP Y FUJIWARA and others . AVP-and oxytocin-induced glucagon secretion or OT, and the level was 10-12 times the value at the baseline. On the other hand, in V1bRK/K mice, glucagon secretion was not changed, even by co-stimulation of AVP and OT (Fig. 5) . These findings indicated that the effect of simultaneous stimulation of both AVP and OT was additive in V1bRC/C mice but not in V1bRK/K mice, suggesting that AVP and OT secreted glucagon through a single pathway, i.e. the OT receptor-mediating pathway, in V1bRK/K mice.
Discussion
Our study shows that AVP and OT sufficiently stimulate glucagon secretion from mouse islets, as observed in previous reports (Dunning et al. 1984 , Gao et al. 1991 . As reported in the rat (Yibchok-anun et al. 1999) , AVP-and OT-induced glucagon secretion was significantly inhibited by treatment with the V1b receptor and OT receptor antagonists respectively, suggesting that AVP and OT stimulate glucagon secretion via the V1b and the OT receptors respectively, in V1bRC/C mice. However, AVP-induced glucagon secretion was not completely inhibited by 10 K6 M SSR149415, and co-administration of SSR149415 and CL-14-26 further inhibited AVP-induced glucagon secretion, suggesting that the OT receptors could be involved in the mediation of AVP-induced glucagon secretion. Similarly, OT-induced glucagon secretion was not completely inhibited by 10 K6 M CL-14-26 but was further inhibited by the co-administration of SSR149415 and CL-14-26, suggesting that the V1b receptors could also mediate OT-induced glucagon secretion. These observations suggested cross-reactivity between AVP and OT in releasing glucagon from the mouse islets. Since V1a and V2 receptors, the other vasopressin receptor subtypes, do not exist in isolated islets , this cross-reactivity refers to the event involving V1b and OT receptors. Such crossreactivity among the receptor family for AVP and OT has been reported in several tissues. For example, OT stimulated ACTH release at the nanomolar order via the V1b receptor in primary cultured cells of the rat anterior pituitary (Schlosser et al. 1994) , although OT had more than 300-fold higher affinity with the OT receptor than the V1b receptor. In other cases, the AVP acts on the OT receptor to induce the uterine contraction of nonpregnant and pregnant myometrium in mice and humans (Bossmar et al. 1994 , Akerlund et al. 1999 , Kawamata et al. 2003 . Therefore, there could also be a crossreactivity between AVP and OT in the mouse islets. In contrast to the case of glucagon secretion, AVP could not stimulate insulin release from the islets of V1bRK/K mice, suggesting that the V1b receptor could be essential for AVPinduced insulin secretion from the mouse islets and that receptors other than the V1b receptor could not mediate AVP-induced insulin secretion .
The analysis of V1bRK/K mice has revealed that AVP could sufficiently stimulate glucagon secretion under the V1b receptor-deficient condition, since AVP stimulated glucagon secretion as potently in V1bRK/K mice as in V1bRC/C mice. AVP-induced glucagon secretion in V1bRK/K mice was inhibited by the OT receptor antagonist but hardly affected AVP-induced glucagon secretion in V1bRC/C mice. These findings indicated that AVP-induced glucagon secretion via the OT receptors could be activated in V1bRK/K mice. Thus, our study implicated that there was a crossreactivity of AVP to the OT receptor on releasing glucagon and that switching from the V1b to the OT receptors would take place under the V1b receptor-deficient condition. This is the first time that the existence of a compensating system between the V1b and the OT receptors has been revealed. On the other hand, OT has been reported to stimulate glucagon secretion via the V1b receptor in In-R1-G9, a hamster clonal a cell line (Yibchok-anun & Hsu 1998) . Because this cell line has low affinity for OT (Folny et al. 2003) , which indicates that the OT receptors could be rarely expressed in this cell line, the signaling pathways via the V1b receptors on OT-induced glucagon secretion could be activated in this cell line. Thus, it is likely that the compensating mechanisms between the V1b and the OT receptors could be interchangeable and that AVP and OT could have different efficacy to the V1b and the OT receptors depending on their population and predominance.
In conclusion, our studies with mutant mice and receptorselective antagonists clearly demonstrate that AVP and OT may induce glucagon secretion through a dual pathway, which is mediated by either the V1b and OT receptors or the OT receptor in the case of V1b receptor deficiency. The plasma concentration of AVP and OT is approximately 10 K12 M in humans (Baylis et al. 1981 , Volpi et al. 1998 ). Since 10
K9
-10 K7 M AVP and OT was used in the present study, it is unlikely that glucagon secretion occurred via the V1b and OT receptor stimulation under normal conditions. However, when diseases such as severe septic shock and congestive heart failure occur, it is known that the plasma AVP level increases approximately 10 K11 -10 K9 M (Riegger et al. 1982 , Lodha et al. 2006 . In addition, i.v. injections of AVP and OT induce glucagon secretion in humans (Spruce et al. 1985) . Thus, the cross-reactivity of V1b and OT receptors may be physiologically relevant in some severe disease cases. Our results suggest that it is necessary to consider the possibility that a substitution by other receptors of the same family is caused by the regulation of one receptor. The selective drugs targeting these two receptors could control glucagon secretion, contributing to the regulation of the blood glucose level as novel therapeutic agents.
